GOG-3119 (MK2870-033): Randomized, Open-Label Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-Line Maintenance Treatment in Pts with pMMR Endometrial Cancer

Inclusion:   

• Advanced (Stage III/IV) or recurrent endometrial cancer

• pMMR

• Measurable Stage III; Measurable or Non-Measurable Stage IV or recurrent (ALL STAGES MUST HAVE EVALUABLE DISEASE ON SCANS)

• May have 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemo in the setting of curative intent.  This may have been given as treatment involving chemo alone, concurrent chemoradiation or as part of a sequential approach such as in a regimen involving concurrent chemoradiation followed by chemo

• May have received prior radiation with or without radiosensitizing chemo if ˃2 weeks before the start of induction chemo

• Unlimited number of prior hormone tx lines

Exclusion:

• Carcinosarcoma, neuroendocrine or sarcoma

• Known POLE mutation

• dMMR

• Is a candidate for curative-intent surgery or radiotherapy

• Prior anti-PD-1/L1/L2 or agent directed to another stimulatory or coinhibitory T-cell receptor (ie CTLA-4); Prior Trop2 ADC

Requirements:

• Pts must be advised to avoid tobacco and alcohol